Please login to the form below

Not currently logged in
Email:
Password:

Swedish Orphan Biovitrum

This page shows the latest Swedish Orphan Biovitrum news and features for those working in and with pharma, biotech and healthcare.

US, EU regulators back rapid reviews of AZ’s RSV med

US, EU regulators back rapid reviews of AZ’s RSV med

With MEDI8897, AZ and its partners for the drug – Sanofi and Swedish Orphan Biovitrum (Sobi) – have the opportunity to open up the RSV prevention market beyond high-risk patients, as its

Latest news

More from news
Approximately 4 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    Orphan Biovitrum) a company that, as its name suggests, is entirely dedicated to rare conditions. ... The UK, in common with many developed markets, has large numbers of products that, while they do have a licence and are currently available, are rarely

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    49. †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum.  Development, supply and commercialisation. Xiapex (collagenase clostridium histolyticum) (approved)  .  40. All deals are worldwide unless otherwise noted – see below:.   .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Say Communications

    Roche Diabetes Care. Swedish Orphan Biovitrum. Target Ovarian Cancer. Trudell Medical.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics